HRP20010123B1 - New oral formulation 5-ht4 agonists or antagonists - Google Patents

New oral formulation 5-ht4 agonists or antagonists

Info

Publication number
HRP20010123B1
HRP20010123B1 HR20010123A HRP20010123A HRP20010123B1 HR P20010123 B1 HRP20010123 B1 HR P20010123B1 HR 20010123 A HR20010123 A HR 20010123A HR P20010123 A HRP20010123 A HR P20010123A HR P20010123 B1 HRP20010123 B1 HR P20010123B1
Authority
HR
Croatia
Prior art keywords
agonists
antagonists
oral formulation
new oral
sodium
Prior art date
Application number
HR20010123A
Other languages
English (en)
Croatian (hr)
Inventor
De Bruijn Karel
Engel Guenter
Pfannkuche Hans-Juergen
Thewissen Michael
Vitzling Christian
Zueger Othmar
Original Assignee
Novartis Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010123(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Aktiengesellschaft filed Critical Novartis Aktiengesellschaft
Publication of HRP20010123A2 publication Critical patent/HRP20010123A2/hr
Publication of HRP20010123B1 publication Critical patent/HRP20010123B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Cosmetics (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Peptides Or Proteins (AREA)
HR20010123A 1998-08-21 2001-02-20 New oral formulation 5-ht4 agonists or antagonists HRP20010123B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds
PCT/EP1999/006083 WO2000010526A2 (en) 1998-08-21 1999-08-19 New oral formulation for 5-ht4 agonists or antagonists

Publications (2)

Publication Number Publication Date
HRP20010123A2 HRP20010123A2 (en) 2002-02-28
HRP20010123B1 true HRP20010123B1 (en) 2010-11-30

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010123A HRP20010123B1 (en) 1998-08-21 2001-02-20 New oral formulation 5-ht4 agonists or antagonists

Country Status (30)

Country Link
US (4) US20030236183A1 (da)
EP (1) EP1104289B1 (da)
JP (1) JP4048024B2 (da)
KR (1) KR100529659B1 (da)
CN (2) CN1165293C (da)
AT (1) ATE316782T1 (da)
AU (4) AU762829B2 (da)
BG (1) BG65322B1 (da)
BR (1) BR9913135A (da)
CA (1) CA2338794C (da)
CZ (1) CZ300647B6 (da)
DE (1) DE69929703T2 (da)
DK (1) DK1104289T3 (da)
EE (1) EE05054B1 (da)
ES (1) ES2257869T3 (da)
FR (3) FR2782454B1 (da)
HK (1) HK1038179A1 (da)
HR (1) HRP20010123B1 (da)
HU (1) HU228179B1 (da)
ID (1) ID28510A (da)
IL (1) IL141236A0 (da)
IS (1) IS2369B (da)
IT (1) IT1314185B1 (da)
NO (1) NO328756B1 (da)
NZ (1) NZ509832A (da)
PL (2) PL194069B1 (da)
RS (1) RS50104B (da)
SK (1) SK285255B6 (da)
TR (3) TR200400187T2 (da)
WO (1) WO2000010526A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743820B2 (en) 2000-07-07 2004-06-01 University Of Toledo Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EP3332772A1 (en) 2009-10-30 2018-06-13 IX Biopharma Ltd Fast dissolving solid dosage form
WO2013026565A1 (de) 2011-08-20 2013-02-28 Advanced Medical Balloons Trans-analer einlaufkatheter und verfahren zur intermittierenden auslösung einer reflexkoordinierten defäkation
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01156909A (ja) * 1987-09-02 1989-06-20 Chugai Pharmaceut Co Ltd 持続放出製剤
EP0505322A1 (en) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
EP0691340A1 (en) * 1994-07-05 1996-01-10 Sanwa Kagaku Kenkyusho Co., Ltd. 1-Azabicyclo 3.3.0 octan derivative, salt thereof, process for the preparation of same and use thereof
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
WO1996016639A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
EP0732333A1 (en) * 1995-03-16 1996-09-18 Eli Lilly And Company Indazolecarboxamides
WO1997022335A1 (en) * 1995-12-19 1997-06-26 Abbott Laboratories A controlled release formulation for poorly soluble basic drugs
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
WO1998003173A1 (en) * 1996-07-19 1998-01-29 Sepracor Inc. Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196A1 (fr) * 1996-09-12 1998-03-13 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
DK0472502T3 (da) * 1990-08-24 1995-10-09 Spirig Ag Fremgangsmåde til fremstilling af pellets
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (da) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
NZ505123A (en) * 1997-12-19 2003-07-25 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01156909A (ja) * 1987-09-02 1989-06-20 Chugai Pharmaceut Co Ltd 持続放出製剤
EP0505322A1 (en) * 1991-03-22 1992-09-23 Sandoz Ltd. Aminoguanidines
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
EP0691340A1 (en) * 1994-07-05 1996-01-10 Sanwa Kagaku Kenkyusho Co., Ltd. 1-Azabicyclo 3.3.0 octan derivative, salt thereof, process for the preparation of same and use thereof
WO1996016639A1 (en) * 1994-12-01 1996-06-06 Cibus Pharmaceutical, Inc. Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
EP0732333A1 (en) * 1995-03-16 1996-09-18 Eli Lilly And Company Indazolecarboxamides
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
WO1997022335A1 (en) * 1995-12-19 1997-06-26 Abbott Laboratories A controlled release formulation for poorly soluble basic drugs
WO1998003173A1 (en) * 1996-07-19 1998-01-29 Sepracor Inc. Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196A1 (fr) * 1996-09-12 1998-03-13 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
ES2257869T3 (es) 2006-08-01
BG65322B1 (bg) 2008-02-29
CN1165293C (zh) 2004-09-08
KR20010079668A (ko) 2001-08-22
FR2782454A1 (fr) 2000-02-25
AU2003248212A1 (en) 2003-10-30
PL200132B1 (pl) 2008-12-31
ATE316782T1 (de) 2006-02-15
CN1589906A (zh) 2005-03-09
AU2006200048A1 (en) 2006-02-02
SK285255B6 (sk) 2006-09-07
CZ300647B6 (cs) 2009-07-08
US20130158092A1 (en) 2013-06-20
WO2000010526A2 (en) 2000-03-02
EP1104289A2 (en) 2001-06-06
ID28510A (id) 2001-05-31
KR100529659B1 (ko) 2005-11-21
US20080075773A1 (en) 2008-03-27
HU228179B1 (en) 2013-01-28
FR2782454B1 (fr) 2005-12-02
CA2338794A1 (en) 2000-03-02
WO2000010526A3 (en) 2000-09-08
CA2338794C (en) 2009-01-20
NZ509832A (en) 2003-11-28
US20030236183A1 (en) 2003-12-25
ITMI991826A0 (it) 1999-08-19
NO20010863D0 (no) 2001-02-20
TR200102259T2 (tr) 2002-06-21
DE69929703T2 (de) 2007-02-22
JP2002523351A (ja) 2002-07-30
HUP0103431A3 (en) 2002-02-28
HUP0103431A2 (hu) 2002-01-28
TR200100361T2 (tr) 2001-06-21
HK1038179A1 (en) 2002-03-08
EE200100104A (et) 2002-06-17
NO20010863L (no) 2001-03-26
EP1104289B1 (en) 2006-02-01
AU2009200403A1 (en) 2009-02-26
FR2799123A1 (fr) 2001-04-06
BG105257A (en) 2001-11-30
PL346764A1 (en) 2002-02-25
FR2784899A1 (fr) 2000-04-28
DK1104289T3 (da) 2006-05-15
HRP20010123A2 (en) 2002-02-28
IL141236A0 (en) 2002-03-10
NO328756B1 (no) 2010-05-03
IT1314185B1 (it) 2002-12-06
SK2432001A3 (en) 2001-09-11
RS50104B (sr) 2009-01-22
FR2784899B1 (fr) 2001-08-17
ITMI991826A1 (it) 2001-02-19
EE05054B1 (et) 2008-08-15
DE69929703D1 (de) 2006-04-13
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
PL194069B1 (pl) 2007-04-30
JP4048024B2 (ja) 2008-02-13
US20120071537A1 (en) 2012-03-22
AU762829B2 (en) 2003-07-03
IS2369B (is) 2008-06-15
TR200400187T2 (tr) 2006-11-21
BR9913135A (pt) 2001-05-08
FR2799123B1 (fr) 2005-12-02
CN1323200A (zh) 2001-11-21
YU8701A (sh) 2003-12-31
AU5623299A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
HRP20010123B1 (en) New oral formulation 5-ht4 agonists or antagonists
MEP33708A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
EP1630157A4 (en) ANTAGONIST OF CASR
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
SE0302760D0 (sv) New compounds
RS53690B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LEVETIRACETAM AND THE PROCESS FOR THEIR PREPARATION
MY134568A (en) Cb2 receptor agonists
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
MEP49308A (en) Once-a-day oxycodone formulations
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
HUP0101439A2 (hu) A II antagonistát tartalmazó nyújtott felszabadulású készítmény, valamint eljárás ennek előállítására és alkalmazása
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
HRP20040996B1 (en) High drug load tablet
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
HRP20010243B1 (en) Compositions containing diphosphonic acids
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
MY139546A (en) 5ht4 partial agonist pharmaceutical compositions
BG104916A (en) Calcilytic compounds
NZ505613A (en) Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180730

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20190819